Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Key facts

Sponsor

Radiation Therapy Oncology Group

Principal Investigator

Andy M. Trotti, MD

H. Lee Moffitt Cancer Center and Research Institute

Intervention

cetuximab(biological)

Enrollment

987 enrolled

Eligibility

18-120 years · All sexes

Timeline

2011 – 2025

Study locations (30)

• Providence Cancer Center, Anchorage, Alaska, United States
• Auburn Radiation Oncology, Auburn, California, United States
• Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States
• Radiation Oncology Centers - Cameron Park, Cameron Park, California, United States
• Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States
• Enloe Cancer Center at Enloe Medical Center, Chico, California, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
• Kaiser Permanente - Division of Research - Oakland, Oakland, California, United States
• Rohnert Park Cancer Center, Rohnert Park, California, United States
• Radiation Oncology Center - Roseville, Roseville, California, United States
• Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
• Mercy General Hospital, Sacramento, California, United States
• UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
• Santa Clara, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · NRG Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07088211
  Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital

See all trials for Squamous cell carcinoma of head and neck →